Merck & Co and Takeda are in line for exits when drug developer NGM Biopharmaceuticals lists on the Nasdaq Global Select Market.

The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.

Liulishuo has listed on the New York Stock Exchange following a $71.9m initial public offering that provided an exit to publishing house Hearst.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.

The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

The home IoT platform floated at the foot of its range to raise almost $103m, while Xiaomi will retain a 16.4% stake in the company.

The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.